


The Majority of Clinical Phase Antiviral Compound/Indications Are Targeting Coronaviruses and Orthomyxoviruses*


% Clinical Phase Antiviral Compound/Indications by Virus Family (N=80)



*As of November 16, 2023

The Majority of Clinical Phase Antiviral Compound/Indications Are Targeting Coronaviruses and Orthomyxoviruses*

% Clinical Phase Antiviral Compound/Indications by Virus Family (N=80)



*As of November 16, 2023



INTREPID ALLIANCE
INTERNATIONAL READINESS FOR PREVENTING INFECTIOUS VIRAL DISEASE

Interested
in engaging
with us?

For more information, contact
nina@intrepidalliance.org.

 intrepidalliance.org

 linkedin.com/company/intrepid-alliance